Malotilate
(Synonyms: 马洛替酯; NKK 105) 目录号 : GC14751
A hepatoprotective agent
Cas No.:59937-28-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: N/A
Malotilate (diisopropyl-l,3-dithiol-2-ylidenemalonate) is a novel hepatotrophic drug, which can improve protein metabolism and stimulate hepatocyte regeneration.
In vitro: The in-vitro invasion assay employing a rat lung endothelial cell monolayer indicated that pretreatment of the lung endothelial cells, but not c-SST-2 cells, with malotilate reduced the invasion of the RLE monolayer by c-SST-2 cells significantly. The in-vitro vascular permeability assay also demonstrated malotilate could prevent the permeability increase of the lung endothelial cell monolayer by serum starvation. In contrast, the gelatinase production and adhesion to the RLE cell monolayer of c-SST-2 cells were not affected by malotilate treatment [1].
In vivo: Malotilate was administered to syngeneic SHR rats orally from 7 days before or after s.c. inoculation of c-SST-2 cells until the end of the experiments. In the malotilate-treated rats, pulmonary metastasis was suppressed markedly when compared with the non-treated rats. Moreover, in the rats treated with malotilate for 19 days after inoculation of c-SST-2 cells, lung metastasis was also suppressed significantly [1].
Clinical trial: A previous clinical trial results indicated that malotilate could accelerate the recovery of impaired protein metabolism in alcoholic liver disease and thus malotilate might be useful for the treatment of alcoholic liver diseases [2].
References:
[1] Nagayasu H,Hamada J,Kawano T,Konaka S,Nakata D,Shibata T,Arisue M,Hosokawa M,Takeichi N,Moriuchi T. Inhibitory effects of malotilate on invasion and metastasis of rat mammary carcinoma cells by modifying the functions of vascular endothelial cells. Br J Cancer.1998 May;77(9):1371-7.
[2] Takase S,Matsuda Y,Yasuhara M,Takada A. Effects of malotilate treatment on alcoholic liver disease. Alcohol.1989 May-Jun;6(3):219-22.
| Cas No. | 59937-28-9 | SDF | |
| 别名 | 马洛替酯; NKK 105 | ||
| 化学名 | dipropan-2-yl 2-(1,3-dithiol-2-ylidene)propanedioate | ||
| Canonical SMILES | CC(C)OC(=O)C(=C1SC=CS1)C(=O)OC(C)C | ||
| 分子式 | C12H16O4S2 | 分子量 | 288.38 |
| 溶解度 | ≥ 14.4mg/mL in DMSO | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4676 mL | 17.3382 mL | 34.6765 mL |
| 5 mM | 0.6935 mL | 3.4676 mL | 6.9353 mL |
| 10 mM | 0.3468 mL | 1.7338 mL | 3.4676 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。